Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma

Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity

(2020) Ilgen Mender et al.   CANCER CELL

Cell Cycle Regulation Meets Tumor Immunosuppression

(2020) Jinyang Li et al.   TRENDS IN IMMUNOLOGY

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy

(2020) Diana Malarikova et al.   Cancers

CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade

(2020) Guangchuan Wang et al.   Cancer Discovery

UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors

(2019) Ron D. Jachimowicz et al.   CELL

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients

(2019) Andrea Mareckova et al.   LEUKEMIA & LYMPHOMA

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

Germinal center‐derived lymphomas: The darkest side of humoral immunity

(2019) Coraline Mlynarczyk et al.   IMMUNOLOGICAL REVIEWS

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

(2019) Peter Martin et al.   BLOOD

DNA double-strand break repair pathway choice - from basic biology to clinical exploitation

(2019) Ron D. Jachimowicz et al.   CELL CYCLE

A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma

(2019) Peter Martin et al.   LEUKEMIA & LYMPHOMA

Class-Switch Recombination Occurs Infrequently in Germinal Centers

(2019) Jonathan A. Roco et al.   IMMUNITY

ATM activity in T cells is critical for immune surveillance of lymphoma in vivo

(2019) Arina Riabinska et al.   LEUKEMIA

STING: a master regulator in the cancer-immunity cycle

(2019) Yuanyuan Zhu et al.   Molecular Cancer

Synthetic lethality as an engine for cancer drug target discovery

(2019) Alan Huang et al.   NATURE REVIEWS DRUG DISCOVERY

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells

(2019) Tatiana N. Moiseeva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer

(2019) Hua Zhang et al.   CANCER CELL

CDK4/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair

(2019) Xianhe Xie et al.   OncoTargets and Therapy

Comprehensive Characterization of Cancer Driver Genes and Mutations

(2018) Matthew H. Bailey et al.   CELL

DNA damage pathways and B-cell lymphomagenesis

(2018) Gero Knittel et al.   CURRENT OPINION IN HEMATOLOGY

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

(2018) Max D. Wellenstein et al.   IMMUNITY

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

(2018) Jinyang Li et al.   IMMUNITY

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

(2018) David A. Schaer et al.   Cell Reports

Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair

(2018) Dominika Tempka et al.   Redox Biology

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

(2018) Diana Miao et al.   NATURE GENETICS

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

(2018) Livnat Jerby-Arnon et al.   CELL

NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

(2018) Marcus Ruscetti et al.   SCIENCE

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

(2018) Liya Ding et al.   Cell Reports

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest

(2017) Ashleigh M. Francis et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer

(2017) Ana Alcaraz-Sanabria et al.   MOLECULAR CANCER THERAPEUTICS

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

(2017) Steven Lemery et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells

(2017) Thuy-Vy Do et al.   Oncotarget

Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells

(2016) Chih-Hang Anthony Tang et al.   CANCER RESEARCH

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer

(2016) David Balli et al.   CLINICAL CANCER RESEARCH

Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

(2016) Yana Pikman et al.   CLINICAL CANCER RESEARCH

Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival

(2016) Sonja M. Wörmann et al.   GASTROENTEROLOGY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

The cell cycle restricts activation-induced cytidine deaminase activity to early G1

(2016) Qiao Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ATM Mutations in Cancer: Therapeutic Implications

(2016) M. Choi et al.   MOLECULAR CANCER THERAPEUTICS

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

(2016) Jessica S. Brown et al.   Cancer Discovery

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

(2016) Sara Costa-Cabral et al.   PLoS One

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

(2015) M.-H. Delfau-Larue et al.   BLOOD

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Aurora B Overexpression Causes Aneuploidy and p21Cip1Repression during Tumor Development

(2015) Alejandra González-Loyola et al.   MOLECULAR AND CELLULAR BIOLOGY

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

(2015) T. Higuchi et al.   Cancer Immunology Research

Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

(2014) B. Holkova et al.   CLINICAL CANCER RESEARCH

Genetic Variation in DNA Repair Pathways and Risk of Non-Hodgkin's Lymphoma

(2014) Justin Rendleman et al.   PLoS One

Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches

(2014) Felix Dietlein et al.   TRENDS IN GENETICS

Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer

(2013) Tomer Cooks et al.   CANCER CELL

DNA repair genes are selectively mutated in diffuse large B cell lymphomas

(2013) Noel FCC de Miranda et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fanconi anaemia and the repair of Watson and Crick DNA crosslinks

(2013) Molly C. Kottemann et al.   NATURE

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response

(2013) H. Christian Reinhardt et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The ATM protein kinase: regulating the cellular response to genotoxic stress and more

(2013) Yosef Shiloh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The Response to and Repair of RAG-Mediated DNA Double-Strand Breaks

(2012) Beth A. Helmink et al.   Annual Review of Immunology

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma

(2012) Yanwen Jiang et al.   PLoS One

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

(2011) Wenqing Qi et al.   BIOCHEMICAL PHARMACOLOGY

Exploiting synthetic lethal interactions for targeted cancer therapy

(2011) H. Christian Reinhardt et al.   CELL CYCLE

Coupling of V(D)J Recombination to the Cell Cycle Suppresses Genomic Instability and Lymphoid Tumorigenesis

(2011) Li Zhang et al.   IMMUNITY

Abnormalities of DNA repair mechanisms in common hematological malignancies

(2011) Panagiota Economopoulou et al.   LEUKEMIA & LYMPHOMA

The combined status of ATM and p53 link tumor development with therapeutic response

(2009) H. Jiang et al.   GENES & DEVELOPMENT

Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance

(2009) L. S. Waters et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival

(2008) D. O'Shea et al.   BLOOD